Sanofi's adoption of FDA-selected flu strains is a strategic move to ensure its vaccine portfolio is ready for the upcoming flu season. This proactive approach is likely to positively impact Sanofi's market position and investor confidence, as it demonstrates the company's commitment to meeting regulatory standards and market demand.